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Role of Lead-binding Proteins in Renal Cancer
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High-dose lead exposure in rodents has been shown to produce pathognomonic lead intranuclear inclusion bodies and to result in an increased inci-
dence of renal adenocarcinomas. Studies from this laboratory and others have demonstrated the presence of high-affinity renal lead-binding proteins
in rat kidneys which act as tissue sinks for lead at low dose levels. Cell-free nuclear translocation studies have shown that these molecules are capa-
ble of facilitating the intranuclear movement of lead and that they are associated with chromatin. These data suggest that renal lead-binding proteins
may play a role in mediating known alterations in renal gene expression associated with formation of intranuclear inclusion bodies. More recent stud-
ies from this laboratory have demonstrated the presence of chemically similar lead-binding proteins in kidneys of both monkeys and humans. Such
observations suggest that a similar mechanism may be operating in primates since lead intranuclear inclusion bodies are also observed in these
species. These data provide a testable mechanistic approach for assessing the possible role(s) of lead-binding proteins in mediating the intranuclear
movement of lead and lead-induced renal cancer in primate species. - Environ Health Perspect 102(Suppl 3):115-116 (1994).
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Introduction
Chronic exposure to high dosages of lead
has been known for many years to produce
a marked increase in the incidence ofrenal
adenocarcinoma in rodents (1,2). However,
the lower end ofthe dose-response curve or
the underlying mechanism(s) for this effect
have not been delineated. The possible rel-
evance ofthese data to renal adenocarcinomas
in humans is not clear. Studies have shown
that chronic exposure to lead acetate or
acute intravenous injection of lead in rats
and mice produces a marked stimulation of
mitosis in renal proximal tubule cells. Such
exposures are also associated with increases
in total DNA, RNA, and protein synthesis
in the kidneys of these animals (3-5).
More recent intravenous injection studies
(6) have shown that there is both up- and
down-regulation of a number ofgene prod-
ucts in rat kidneys which is temporally
linked with the reversible formation of
lead-induced intranuclear inclusion bodies.
In other words, there is a clear relationship
between the presence of lead within the
nucleus and a number of specific alter-
ations in renal gene expression.
At present, the exact molecular mecha-
nisms underlying the above processes are
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unclear. It has been hypothesized (7,8)
that kidney-specific lead-binding proteins
(8,9), which are capable of facilitating the
intranuclear movement of lead and its
binding to DNA (6,10), may act as tissue-
specific "receptors" for lead; this may
explain why only certain cells in certain tis-
sues are preferentially affected by this metal.
The renal lead-binding protein in rats was
found to be an N-terminal cleavage prod-
uct ofa-2p-globulin (8), which underwent
aggregation in the presence of lead (11).
This suggests that the protein plays an early
role in the formation oflead inclusion bodies
in both the cytoplasm and the nucleus.
More recently, studies in this laboratory
have demonstrated the presence of chemi-
cally similar but immunologically distinct
renal lead-binding proteins in monkeys
(12) and humans (13,14). The presence of
these lead-binding molecules in primate
species suggests that they may play a similar
role with regard to mediating the low-dose
effects oflead in the kidney. Research is in
progress to identify these proteins in pri-
mates via N-terminal sequence analyses so
that a clearer picture of how the proteins
relate to those in rodents may be established.
This information may provide a useful
"bridge" between rats, monkeys, and
humans for risk assessment (12), and may
provide a mechanistic basis for determining
possible linkages between lead-induced
renal adenocarcinomas in rodents and in
workers exposed to lead (15-17).
The role of lead-binding proteins in
mediating renal cancer in rodents (and pos-
sibly in primates) may be explored through
the following working hypothesis: the renal
carcinogenic effects of lead are mediated
through a group of processed kidney-spe-
cific proteins which act as receptors for lead
and facilitate its intranuclear movement
and interactions with DNA in renal proxi-
mal tubule cells. This in turn leads to cancer
via chronic altered renal gene expression,
including expression ofsome oncogenes, in
those cells.
The probability ofsuch an event occur-
ring in a given individual is thus directly
proportional to the tissue concentrations of
the lead-binding proteins in the target cell
population (renal proximal tubule cells)
and not only the administered dosage or
total tissue concentration of lead. A dia-
grammatic representation ofthis hypothesis
is presented in Figure 1. This hypothesis is
based upon studies in rats, and it is not clear
whether the proteins identified in monkeys
and humans behave in a similar manner.
Two lines ofevidence that support this
working hypothesis, aside from that listed
in the introduction, are the following:
(a) Lead-binding proteins are found in
highest concentrations in target cell popu-
lations. Immunohistochemical studies of
renal proximal tubule cells using a poly-
clonal antibody showed that only certain
clusters of cells stained positive for ct-2p-
globulin (8), indicating that not all cells
contained this protein. This is consistent
with the idea that cancerous cells arise from
discrete loci within proximal tubule cell
populations. Intercellular differences in the
presence ofa-2p-globulin may have a phys-
iologic basis, since only certain nephrons
are operational under normal conditions.
Further, the observed presence of ct-2p-
globulin in nuclear and cytoplasmic areas,
in addition to lysosomes, is consistent with
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Figure 1. Diagram of renal proximal tubule cell showing
hypothesized mechanism by which reabsorbed lead-bind-
ing proteins could alter renal gene expression, activate
oncogenes, and ultimately leadtocellulartransformation.
the idea that certain populations of proxi-
mal tubule cells preferentially take up this
protein because they possess the necessary
receptors on their apical surfaces.
(b) The renal lead-binding protein
facilitates the intranuclear transport of
lead and binding to DNA. Cell-free
nuclear translocation studies have shown
that the renal lead-binding protein facili-
tated the intranuclear transport of lead
into renal nuclei, and they provided evi-
dence of chromatin binding of the lead-
binding protein complex (6,10). Binding
of lead to the lead-binding protein and
the nuclear uptake of this complex was
also effected by in vitro levels ofcadmium
and zinc. Cadmium greatly inhibited the
nuclear uptake of lead-binding protein,
while zinc actually increased nuclear
uptake. This effect of cadmium is consis-
tent with other in vivo studies in which
intranuclear inclusions did not form in
renal proximal tubule cells from rats con-
currently exposed to both lead and cad-
mium, while they did form in animals
receiving only lead (18).
These observations, combined with
the data ofDuVal et al. (11) indicate that
the renal lead-binding protein may be the
mechanism by which lead enters renal
proximal cell nuclei, and that the lead-
binding protein aggregation phenomenon
observed in vitro is an initial step in the
formation of intranuclear inclusion bod-
ies. The observation that zinc is a highly
effective competitor to lead and facilitates
the nuclear uptake of lead-binding pro-
tein suggests that it is the normal metal
cofactor for this protein. This is consis-
tent with some studies ofhormone recep-
tors, in which zinc enhanced the nuclear
uptake ofspecific target molecules.
Conclusions
The above-mentioned data suggest that
the renal lead-binding protein shares a
number of properties with receptors for
other biologically active molecules such as
hormones. It may be that the lead-bind-
ing protein (in rodents) acts in a similar
manner as those other biologically active
molecules, and that lead substitutes for
zinc, thereby altering its normal biologi-
cal activity. Implicit in this idea is the
concept that this metal-binding protein(s)
is normally acting as an interorgan system
messenger capable of regulating renal
gene expression. This brief overview is
intended to provide a testable hypothesis
for explaining how lead could produce
renal cancer in rodents, and perhaps in
primates as well, by leading to the expres-
sion of elevated levels of these metal-
binding proteins.
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